Uttarakhand Suspends Permissions Of 14 Products Of Ramdev’s Pharma Firms

Haridwar: An Indian state regulator has suspended manufacturing licences of 14 products made by pharmaceutical companies of the country’s most popular yoga guru for repeatedly publishing misleading advertisements about their efficacy, a government order showed.

The order is the latest setback for Baba Ramdev whose TV shows, yoga cures and traditional medicine offerings for diseases have made him popular in India and other nations.

The Supreme Court of India has in recent weeks repeatedly criticised Ramdev for not complying with its directives in an ongoing lawsuit to stop misleading advertisements of some of his traditional ayurvedic medicines.

The manufacturing permits of Ramdev’s companies were suspended in an April 15 order by the drug regulator of traditional medicines in northern Uttarakhand state. Reuters is the first to report the order which is not public.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit